Latest news

• J&J’s multiple sclerosis therapy Ponvory moves closer to EU approval

  J&J's pharma division Janssen announced today that the  CHMP recommends approval of the marketing authorisation for Ponvory (ponesimod), for the treatment of adult patients with relapsing MS (RMS), with ... Despite continuous innovations in the

• J&J’s MS drug ponesimod receives approval in the US

  Johnson &Johnson’s (J&J) pharma division Janssen has announced that the US Food and Drug Administration (FDA) has approved its multiple sclerosis (MS) treatment ponesimod, under the brand name Ponvory.

• J&J aims for US approval of MS drug ponesimod

  J&J acquired the S1P receptor modulator as part its $30bn takeover of Actelion, with the FDA application based on the head-to-head phase 3 OPTIMUM study comparing ponesimod to ... Data from that trial showed that treatment with ponesimod was associated

• J&J’s ponesimiod tops Aubagio in head-to-head MS trial

  Sets up regulatory filings and possible approval next year. Johnson &Johnson’s oral multiple sclerosis (MS) therapy ponesimod outperformed Sanofi blockbuster Aubagio in a phase 3 comparative trial, setting up regulatory ... Ponesimod, a S1P receptor

• J&J agrees $30bn deal to acquire Actelion

  J&J also takes control of Actelion's late-stage pipeline, including multiple sclerosis candidate ponesimod and cadazolid for diarrhoeal disease, and the US group has also taken an option on